{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T06:21:59Z","timestamp":1773296519500,"version":"3.50.1"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2011,1,4]],"date-time":"2011-01-04T00:00:00Z","timestamp":1294099200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Therapy"],"published-print":{"date-parts":[[2011,2]]},"DOI":"10.1007\/s12325-010-0098-2","type":"journal-article","created":{"date-parts":[[2011,1,8]],"date-time":"2011-01-08T09:03:33Z","timestamp":1294477413000},"page":"160-171","source":"Crossref","is-referenced-by-count":16,"title":["A crossover study of rosuvastatin and pitavastatin in patients with type 2 diabetes"],"prefix":"10.1007","volume":"28","author":[{"given":"Kazunori","family":"Yanagi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsuyoshi","family":"Monden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shiori","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mihoko","family":"Matsumura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kikuo","family":"Kasai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,4]]},"reference":[{"key":"98_CR1","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/1475-2840-6-25","volume":"6","author":"J.P. Greving","year":"2007","unstructured":"Greving JP, Denig P, Ceeuw D, Bilo HJK, Haaijer-Ruskamp FM. Trend in hyperlipidemia and hypertension management in type 2 diabetes from 1998\u20132004: a longitudinal observational study. Cardiovasc Diabetol. 2007;6:25.","journal-title":"Cardiovasc Diabetol"},{"key":"98_CR2","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1016\/S0140-6736(04)16895-5","volume":"364","author":"H.M. Colhoun","year":"2004","unstructured":"Colhoun HM, Betteridge DJ, Dumington PN, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomized placebo-controlled trial. Lancet. 2004;364:685\u2013696.","journal-title":"Lancet."},{"issue":"Suppl.12A","key":"98_CR3","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.amjmed.2005.09.013","volume":"118","author":"J. Betteridge","year":"2005","unstructured":"Betteridge J. Benefits of lipid-lowering therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(Suppl. 12A):10\u201315.","journal-title":"Am J Med."},{"key":"98_CR4","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","volume":"297","author":"S.J. Nicholls","year":"2007","unstructured":"Nicholls SJ, Tuzcu EM, Sipahi I, et al. Statins, highdensity lipoprotein cholesterol, and regression of coronary atherosclerosis. JAMA. 2007;297:499\u2013508.","journal-title":"JAMA."},{"key":"98_CR5","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1016\/S0140-6736(09)60447-5","volume":"373","author":"P.M. Ridker","year":"2009","unstructured":"Ridker PM, Danielson E, Fonseca FA, et al. Rosuvastatin in C-reactive protein and LDL cholesterol and cardiovascular event rates after initiation of rosuvastatin: a prospective study of the JUPITER trial. Lancet. 2009;373:1175\u20131182.","journal-title":"Lancet."},{"key":"98_CR6","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0021-9150(01)00712-2","volume":"162","author":"Y. Saito","year":"2002","unstructured":"Saito Y, Yamada N, Teramoto T, et al. A randomized, double-blind trial comparing the efficacy and safety of pitavastatin versus pravastatin in patients with primary hypercholesterolemia. Atherosclerosis. 2002;162:373\u2013379.","journal-title":"Atherosclerosis."},{"key":"98_CR7","doi-asserted-by":"crossref","unstructured":"Effects of pitavastatin, 3-hyfroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. J Atheroscler Thromb. 2009;16:539\u2013545.","DOI":"10.5551\/jat.281"},{"key":"98_CR8","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.5551\/jat.5660","volume":"17","author":"H. Arai","year":"2010","unstructured":"Arai H, Hiro T, Kimura T, et al. More intensive lipid lowering is associated with regression of coronary atherosclerosis in diabetic patients with acute coronary syndrome\u2014sub-analysis of Japan-ACS study. J Atheroscler Thromb. 2010;17:1096\u20131107.","journal-title":"J Atheroscler Thromb."},{"key":"98_CR9","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.2337\/diacare.28.5.1151","volume":"28","author":"P.S. Sever","year":"2005","unstructured":"Sever PS, Poulter NR, Dahlof B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipidlowering arm (ASCOT-LLA). Diabetes Care. 2005;28:1151\u20131157.","journal-title":"Diabetes Care."},{"key":"98_CR10","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2796.2010.02230.x","volume":"268","author":"S.A.E. Peters","year":"2010","unstructured":"Peters SAE, Palmer MK, Grobbee DE, et al. C-reactive protein lowering with rosuvastatin in the METEOR study. J Intern Med. 2010;268:155\u2013161.","journal-title":"J Intern Med."},{"key":"98_CR11","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/j.amjcard.2008.08.014","volume":"102","author":"J. Wlodarczyk","year":"2008","unstructured":"Wlodarczyk J, Sullivan D, Smith M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-tohead randomized controlled trials. Am J Cardiol. 2008;102:1654\u20131662.","journal-title":"Am J Cardiol."},{"key":"98_CR12","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.atherosclerosis.2008.02.008","volume":"201","author":"K. Yokote","year":"2008","unstructured":"Yokote K, Bujo H, Hanaoka H, et al. Multicenter collaborative randomized parallel group comparative study of pitavastatin and atorvastatin in Japanese hypercholesterolemic patients. Collaborative study on hypercholesterolemia during intervention and their benefits for atherosclerosis prevention (CHIBA study). Atherosclerosis. 2008; 201:345\u2013352.","journal-title":"Atherosclerosis."},{"key":"98_CR13","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1253\/circj.CJ-08-1051","volume":"73","author":"T. Toi","year":"2009","unstructured":"Toi T, Taguchi I, Yoneda S, et al. Early effect of lipidlowering therapy with pitavastatin on regression of coronary atherosclerotic plaque-comparison with atorvastatin-. Circ J. 2009;73:1466\u20131472.","journal-title":"Circ J."},{"key":"98_CR14","doi-asserted-by":"crossref","first-page":"45","DOI":"10.5551\/jat.14.45","volume":"14","author":"T. Teramoto","year":"2007","unstructured":"Teramoto T, Sasaki J, Uematsu H, et al. Executive summary of Japan Atherosclerosis Society (JAS) guideline for diagnosis and prevention of atherosclerotic cardiovascular disease for Japanese. J Atheroscler Thromb. 2007; 14:45\u201350.","journal-title":"J Atheroscler Thromb."},{"key":"98_CR15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1056\/NEJMoa021993","volume":"347","author":"P.M. Ridker","year":"2002","unstructured":"Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med. 2002; 347:1557\u20131565.","journal-title":"N Engl J Med."},{"key":"98_CR16","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1161\/01.ATV.0000034543.78801.69","volume":"22","author":"T.J. Wang","year":"2002","unstructured":"Wang TJ, Nam BH, Wilson PW, et al. Association of C-reactive protein with carotid atherosclerosis in men and women: The Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2002;22:1662\u20131667.","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"98_CR17","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1111\/j.1464-5491.2004.01212.x","volume":"21","author":"K. Hashimoto","year":"2004","unstructured":"Hashimoto K, Kasayama S, Yamamoto H, Kurebayashi S, Kawase I, Koga M. Strong association of C-reactive protein with body mass index and 2-h post-challenge glucose in non-diabetic, nonsmoker subjects without hypertension. Diabet Med. 2004;21:581\u2013585.","journal-title":"Diabet Med."},{"key":"98_CR18","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1056\/NEJM199901143400207","volume":"340","author":"R. Ross","year":"1999","unstructured":"Ross R. Atherosclerosis \u2014 an inflammatory disease. N Engl J Med. 1999;340:115\u2013126.","journal-title":"N Engl J Med."},{"key":"98_CR19","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1053\/meta.2002.36312","volume":"51","author":"A. Taniguchi","year":"2002","unstructured":"Taniguchi A, Nagasaka S, Fukushima M, et al. C-reactive protein and insulin resistance in non-obese Japanese type 2 diabetic patients. Metabolism. 2002;51:1578\u20131581.","journal-title":"Metabolism."},{"key":"98_CR20","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.jdiacomp.2004.08.001","volume":"19","author":"K. Tsunoda","year":"2005","unstructured":"Tsunoda K, Arita M, Yukawa M, et al. Retinopathy and hypertension affect serum high-sensitivity C-reactive protein levels in type 2 diabetic patients. J Diabetes Complications. 2005;19:123\u2013127.","journal-title":"J Diabetes Complications."},{"key":"98_CR21","doi-asserted-by":"crossref","first-page":"345","DOI":"10.5551\/jat.E581","volume":"15","author":"H. Koshiyama","year":"2008","unstructured":"Koshiyama H, Taniguchi A, Tanaka K, et al. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai investigation of statin for hyperlipidemic intervention in metabolism and endocrinology (KISHIMEN) investigators. J Atheroscler Thromb. 2008;15:345\u2013350.","journal-title":"J Atheroscler Thromb."},{"key":"98_CR22","doi-asserted-by":"crossref","first-page":"546","DOI":"10.5551\/jat.992","volume":"16","author":"T. Motomura","year":"2009","unstructured":"Motomura T, Okamoto M, Kitamura T, et al. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetes patients. J Atheroscler Thromb. 2009;16:546\u2013552.","journal-title":"J Atheroscler Thromb."},{"key":"98_CR23","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s11095-008-9798-6","volume":"26","author":"H.Y. Qu","year":"2009","unstructured":"Qu HY, Xiao YW, Jiang GH, et al. Effect of atorvastatin versus rosuvastatin on levels of serum lipids inflammatory markers and adiponectin in patients with hypercholesterolemia. Pharm Res. 2009;26:958\u2013964.","journal-title":"Pharm Res."},{"key":"98_CR24","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1157\/13113929","volume":"60","author":"A. Gomez-Garcia","year":"2007","unstructured":"Gomez-Garcia A, Martines Torres G, Ortega-Pierres LE, Rodriguez-Ayala E, Alvarez-Aguilar C. Rosuvastatin and metformin decrease inflammation and oxidative stress in patients with hypertension and dyslipidemia. Rev Esp Cardiol. 2007;60:1242\u20131249.","journal-title":"Rev Esp Cardiol."},{"key":"98_CR25","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/j.atherosclerosis.2009.11.021","volume":"210","author":"A. Bellia","year":"2010","unstructured":"Bellia A, Rizza S, Galli A, et al. Early vascular and metabolic effects of rosuvastatin compared with simvastatin in patients with type 2 diabetes. Atherosclerosis. 2010;210:199\u2013201.","journal-title":"Atherosclerosis."},{"key":"98_CR26","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.atherosclerosis.2007.06.005","volume":"196","author":"H. Laumen","year":"2008","unstructured":"Laumen H, Skurk T, Hauner H. The HMGCoA reductase inhibitor rosuvastatin inhibits plasminogen activator inhibitor-1 expression and secretion in human adipocytes. Atherosclerosis. 2008;196:565\u2013573.","journal-title":"Atherosclerosis."},{"key":"98_CR27","doi-asserted-by":"crossref","first-page":"87","DOI":"10.5551\/jat.E536","volume":"15","author":"H. Ohbayashi","year":"2008","unstructured":"Ohbayashi H. Pitavastatin improves serum resistin levels in patients with hypercholesterolemia. J Atheroscler Thromb. 2008;15:87\u201393.","journal-title":"J Atheroscler Thromb."},{"key":"98_CR28","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1097\/SMJ.0b013e31819bd023","volume":"102","author":"K. Takebayashi","year":"2009","unstructured":"Takebayashi K, Suetsugu M, Matsumoto S, Aso Y, Inukai T. Effects of rosuvastatin and colestimide on metablic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. South Med J. 2009;102:361\u2013368.","journal-title":"South Med J."},{"key":"98_CR29","first-page":"1195","volume":"11","author":"T. Tsutamoto","year":"2009","unstructured":"Tsutamoto T, Yamaji M, Kawahara C, et al. Effect of simvastatin vs. rosuvastatin on adiponectin and haemoglobin A1c levels in patients with nonischaemic chronic heart failure. Eur J Heart Failure. 2009;11:1195\u20131201.","journal-title":"rosuvastatin on adiponectin and haemoglobin A1c levels in patients with nonischaemic chronic heart failure. Eur J Heart Failure."},{"key":"98_CR30","doi-asserted-by":"crossref","first-page":"269","DOI":"10.5551\/jat.E562","volume":"15","author":"T. Yamakawa","year":"2008","unstructured":"Yamakawa T, Takano T, Tanaka S, Kadonosono K, Terauchi Y. Influence of pitavastatin on glucose tolerance in patients with type 2 diabetes mellitus. J Atheroscler Thromb. 2008;15:269\u2013275.","journal-title":"J Atheroscler Thromb."},{"key":"98_CR31","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000112633","volume":"36","author":"N. Inami","year":"2007","unstructured":"Inami N, Nomura S, Shouzu A, et al Effects of pitavastatin on adiponectin in patients with hyperlipidemia. Pathophysiol Haemost Thromb. 2007;36:1\u20138.","journal-title":"Pathophysiol Haemost Thromb."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0098-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12325-010-0098-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-010-0098-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,7]],"date-time":"2019-06-07T18:09:55Z","timestamp":1559930995000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-010-0098-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,4]]},"references-count":31,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2011,2]]}},"alternative-id":["98"],"URL":"https:\/\/doi.org\/10.1007\/s12325-010-0098-2","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,4]]}}}